Curcumin‘s Therapeutic Potential

Kaloyan Kaloyanov; Maya Yotova; Georgi Momekov; Spiro Konstantinov

doi:10.14748/ahp.v5i1.5954

Curcumin‘s Therapeutic Potential

Kaloyan Kaloyanov, Maya Yotova, Georgi Momekov, Spiro Konstantinov

Abstract

Turmeric (Curcuma longa L., Zingiberaceae) is a spice that is widely used in Indian medicine. The spectrum of diseases in which it is applied includes bile and liver diseases, dizziness, sinusitis, rheumatism, sprains and wounds. The main biologically active substance in the turmeric root is curcumin, accompanied by other closely related compounds. For the therapeutic value of curcumin, there are a number of data from experimental studies as well as clinical data. Numerous studies have shown that it has significant anti-tumor and, in particular, anti-myeloma activity, and have discovered prospects for its future use as a medicinal product. Its lability in oral administration as well as potential drug interactions with various drugs restrict its free use in the form of capsule and tablet formulations, but its administration as a spice has only shown benefits to the patients.

Keywords

curcumin, myeloma

Full Text

References

Antiga E, Bonciolini V, Volpi W, Del Bianco E, Caproni M. (2015). Oral curcumin (Meriva) is effective as an adjuvant treatment and is able to reduce IL-22 serum levels in patients with psoriasis vulgaris. BioMed research international, vol. 2015, Article ID 283634, 7 pages

Bengmark S, Mesa MD, Gil A. (2009). Plant-derived health-the effects of turmeric and curcuminoids. Nutricion hospitalaria. 24(3):273-81.

Burgos‐Morón E, Calderón‐Montaño JM, Salvador J, Robles A, López‐Lázaro M. (2010). The dark side of curcumin. International journal of cancer, 126:1771-5.

Garcia-Gomez A, Quwaider D, Canavese M, Ocio EM, Tian Z, Blanco JF, Berger AJ, Ortiz-de-Solorzano C, Hernández- Iglesias T, Martens AC, Groen RW, Mateo-Urdiales J, Fraile S, Galarraga M, Chauhan D, San Miguel JF, Raje N, Garayoa

M. (2014). Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Clin Cancer Res, 20:1542-54.

Gomez-Bougie P, Halliez M, Maïga S, Godon C, Kervoëlen C, Pellat-Deceunynck C, Amiot M. (2015). Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Cancer Biology & Therapy, 16(1):60–5.

Goel A, Kunnumakkara AB, Aggarwal BB. (2008). Curcumin as „Curcumin“: from kitchen to clinic. Biochemical pharmacology, 75:787-809.

Gupta SC, Patchva S, Aggarwal BB. (2013). Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS journal, 15(1):195-218.

Jurenka JS. (2009). Anti-inflammatory Properties of Curcumin, a Major Constituent of Curcuma Longa: A Review of Preclinical and Clinical Research. Alternative Medicine Review, 14(2):141-53

Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Lo Russo L, De Lillo A, Laino L, Lo Muzio L. (2015). Biological and therapeutic activities, and anticancer properties of curcumin (Review). Experimental and Therapeutic medicine, 10(5):1615-23.

Rajkumar SV. (2009). Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance. Clinical Cancer Research, 15(18): 5606–8.

Lebanova H, Getov I, Grigorov E. (2014). Practical tool to assess reliability of web-based medicines information. Medicinski Glasnik, 11(1):221-7.

DOI: http://dx.doi.org/10.14748/ahp.v5i1.5954